Evaluating construct and criterion validity of NeuroScreen in assessing neurocognition among hospitalized Ugandan first-episode psychosis patients
Introduction: Neurocognitive impairment (NCI) is commonly exhibited among patients experiencing their first episode of psychosis. However, there are few resources in many low-income countries, such as Uganda, that allow for the administration of extensive neurocognitive test batteries for the detect...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2023-06-01
|
| Series: | Schizophrenia Research: Cognition |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2215001322000415 |
| _version_ | 1797868329328705536 |
|---|---|
| author | Nana Asiedu Emmanuel Kiiza Mwesiga Dickens Akena Corey Morrison Joy Louise Gumikiriza-Onoria Angel Nanteza Juliet Nakku Nastassja Koen Noeline Nakasujja Wilber Ssembajjwe Christopher M. Ferraris Anthony F. Santoro Dan J. Stein Reuben N. Robbins |
| author_facet | Nana Asiedu Emmanuel Kiiza Mwesiga Dickens Akena Corey Morrison Joy Louise Gumikiriza-Onoria Angel Nanteza Juliet Nakku Nastassja Koen Noeline Nakasujja Wilber Ssembajjwe Christopher M. Ferraris Anthony F. Santoro Dan J. Stein Reuben N. Robbins |
| author_sort | Nana Asiedu |
| collection | DOAJ |
| description | Introduction: Neurocognitive impairment (NCI) is commonly exhibited among patients experiencing their first episode of psychosis. However, there are few resources in many low-income countries, such as Uganda, that allow for the administration of extensive neurocognitive test batteries for the detection of NCI. NeuroScreen is a brief tablet-based neurocognitive assessment battery that can be administered by all levels of healthcare staff. We examined the validity of NeuroScreen to assess neurocognition and detect NCI in first-episode psychosis (FEP) patients in Uganda. Methods: We enrolled 112 participants FEP patients and matched controls at Butabika Mental Referral Hospital. Each participant completed NeuroScreen and a traditionally administered neurocognitive battery: the MATRIC Consensus Cognitive Battery (MCCB). We examined correlations between participant performance on NeuroScreen and the MCCB. A ROC curve determined sensitivity and specificity of NeuroScreen to detect NCI as determined by MCCB criterion. Results: There was a large, statistically significant correlation between overall performance on NeuroScreen and the MCCB [r(112) = 0.64, p < .001]. Small to large correlations were found between tests in the MCCB and NeuroScreen batteries. The ROC curve of NeuroScreen performance to detect MCCB-defined NCI had an area under curve of 0.80 and optimal sensitivity and specificity of 83 % and 60 %, respectively. Conclusion: There was a moderate positive correlation between overall performance on both batteries. NeuroScreen shows promise as a valid assessment battery to assess neurocognition and detect NCI in FEP patients in Uganda. Further studies of NeuroScreen in healthy individuals and in a range of mental disorders are recommended. |
| first_indexed | 2024-04-09T23:55:20Z |
| format | Article |
| id | doaj.art-fbaa7103d53e4c14badec7f71e90ac32 |
| institution | Directory Open Access Journal |
| issn | 2215-0013 |
| language | English |
| last_indexed | 2024-04-09T23:55:20Z |
| publishDate | 2023-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Schizophrenia Research: Cognition |
| spelling | doaj.art-fbaa7103d53e4c14badec7f71e90ac322023-03-17T04:33:09ZengElsevierSchizophrenia Research: Cognition2215-00132023-06-0132100276Evaluating construct and criterion validity of NeuroScreen in assessing neurocognition among hospitalized Ugandan first-episode psychosis patientsNana Asiedu0Emmanuel Kiiza Mwesiga1Dickens Akena2Corey Morrison3Joy Louise Gumikiriza-Onoria4Angel Nanteza5Juliet Nakku6Nastassja Koen7Noeline Nakasujja8Wilber Ssembajjwe9Christopher M. Ferraris10Anthony F. Santoro11Dan J. Stein12Reuben N. Robbins13HIV Center for Behavioral Studies, New York State Psychiatric Institute and Columbia University, 1051 Riverside Drive, New York, NY 10032, United States of America; Corresponding author.Makerere University College of Health Sciences, School of Medicine, Department of Psychiatry, 7072 Upper Mulago Hill, Mulago Hospital Complex, Uganda; Department of Psychiatry and Mental Health, University of Cape Town, Rondebosch, Cape Town, South AfricaMakerere University College of Health Sciences, School of Medicine, Department of Psychiatry, 7072 Upper Mulago Hill, Mulago Hospital Complex, UgandaHIV Center for Behavioral Studies, New York State Psychiatric Institute and Columbia University, 1051 Riverside Drive, New York, NY 10032, United States of AmericaMakerere University College of Health Sciences, School of Medicine, Department of Psychiatry, 7072 Upper Mulago Hill, Mulago Hospital Complex, UgandaButabika National Referral Mental Hospital, Plot 2 Kirombe-Butabika Road, Kampala, UgandaButabika National Referral Mental Hospital, Plot 2 Kirombe-Butabika Road, Kampala, UgandaDepartment of Psychiatry and Mental Health, University of Cape Town, Rondebosch, Cape Town, South Africa; Neuroscience Institute, University of Cape Town, Observatory, Cape Town, South Africa; South African Medical Research Council (SAMRC) Unit on Risk & Resilience in Mental Disorders, Francie van Zijl Drive Parowvallei, Cape Town, South AfricaMakerere University College of Health Sciences, School of Medicine, Department of Psychiatry, 7072 Upper Mulago Hill, Mulago Hospital Complex, UgandaMedical Research Council, Uganda Virus Research Institute & London School of Hygiene and Tropical Medicine, PO Box 49, Entebbe Plot 51-59 Nakiwogo Road, UgandaHIV Center for Behavioral Studies, New York State Psychiatric Institute and Columbia University, 1051 Riverside Drive, New York, NY 10032, United States of AmericaHIV Center for Behavioral Studies, New York State Psychiatric Institute and Columbia University, 1051 Riverside Drive, New York, NY 10032, United States of AmericaDepartment of Psychiatry and Mental Health, University of Cape Town, Rondebosch, Cape Town, South Africa; Neuroscience Institute, University of Cape Town, Observatory, Cape Town, South Africa; South African Medical Research Council (SAMRC) Unit on Risk & Resilience in Mental Disorders, Francie van Zijl Drive Parowvallei, Cape Town, South AfricaHIV Center for Behavioral Studies, New York State Psychiatric Institute and Columbia University, 1051 Riverside Drive, New York, NY 10032, United States of AmericaIntroduction: Neurocognitive impairment (NCI) is commonly exhibited among patients experiencing their first episode of psychosis. However, there are few resources in many low-income countries, such as Uganda, that allow for the administration of extensive neurocognitive test batteries for the detection of NCI. NeuroScreen is a brief tablet-based neurocognitive assessment battery that can be administered by all levels of healthcare staff. We examined the validity of NeuroScreen to assess neurocognition and detect NCI in first-episode psychosis (FEP) patients in Uganda. Methods: We enrolled 112 participants FEP patients and matched controls at Butabika Mental Referral Hospital. Each participant completed NeuroScreen and a traditionally administered neurocognitive battery: the MATRIC Consensus Cognitive Battery (MCCB). We examined correlations between participant performance on NeuroScreen and the MCCB. A ROC curve determined sensitivity and specificity of NeuroScreen to detect NCI as determined by MCCB criterion. Results: There was a large, statistically significant correlation between overall performance on NeuroScreen and the MCCB [r(112) = 0.64, p < .001]. Small to large correlations were found between tests in the MCCB and NeuroScreen batteries. The ROC curve of NeuroScreen performance to detect MCCB-defined NCI had an area under curve of 0.80 and optimal sensitivity and specificity of 83 % and 60 %, respectively. Conclusion: There was a moderate positive correlation between overall performance on both batteries. NeuroScreen shows promise as a valid assessment battery to assess neurocognition and detect NCI in FEP patients in Uganda. Further studies of NeuroScreen in healthy individuals and in a range of mental disorders are recommended.http://www.sciencedirect.com/science/article/pii/S2215001322000415Neurocognitive impairmentFirst episode psychosisNeuroScreenMATRIC consensus cognitive batteryUgandaLow-income country |
| spellingShingle | Nana Asiedu Emmanuel Kiiza Mwesiga Dickens Akena Corey Morrison Joy Louise Gumikiriza-Onoria Angel Nanteza Juliet Nakku Nastassja Koen Noeline Nakasujja Wilber Ssembajjwe Christopher M. Ferraris Anthony F. Santoro Dan J. Stein Reuben N. Robbins Evaluating construct and criterion validity of NeuroScreen in assessing neurocognition among hospitalized Ugandan first-episode psychosis patients Schizophrenia Research: Cognition Neurocognitive impairment First episode psychosis NeuroScreen MATRIC consensus cognitive battery Uganda Low-income country |
| title | Evaluating construct and criterion validity of NeuroScreen in assessing neurocognition among hospitalized Ugandan first-episode psychosis patients |
| title_full | Evaluating construct and criterion validity of NeuroScreen in assessing neurocognition among hospitalized Ugandan first-episode psychosis patients |
| title_fullStr | Evaluating construct and criterion validity of NeuroScreen in assessing neurocognition among hospitalized Ugandan first-episode psychosis patients |
| title_full_unstemmed | Evaluating construct and criterion validity of NeuroScreen in assessing neurocognition among hospitalized Ugandan first-episode psychosis patients |
| title_short | Evaluating construct and criterion validity of NeuroScreen in assessing neurocognition among hospitalized Ugandan first-episode psychosis patients |
| title_sort | evaluating construct and criterion validity of neuroscreen in assessing neurocognition among hospitalized ugandan first episode psychosis patients |
| topic | Neurocognitive impairment First episode psychosis NeuroScreen MATRIC consensus cognitive battery Uganda Low-income country |
| url | http://www.sciencedirect.com/science/article/pii/S2215001322000415 |
| work_keys_str_mv | AT nanaasiedu evaluatingconstructandcriterionvalidityofneuroscreeninassessingneurocognitionamonghospitalizedugandanfirstepisodepsychosispatients AT emmanuelkiizamwesiga evaluatingconstructandcriterionvalidityofneuroscreeninassessingneurocognitionamonghospitalizedugandanfirstepisodepsychosispatients AT dickensakena evaluatingconstructandcriterionvalidityofneuroscreeninassessingneurocognitionamonghospitalizedugandanfirstepisodepsychosispatients AT coreymorrison evaluatingconstructandcriterionvalidityofneuroscreeninassessingneurocognitionamonghospitalizedugandanfirstepisodepsychosispatients AT joylouisegumikirizaonoria evaluatingconstructandcriterionvalidityofneuroscreeninassessingneurocognitionamonghospitalizedugandanfirstepisodepsychosispatients AT angelnanteza evaluatingconstructandcriterionvalidityofneuroscreeninassessingneurocognitionamonghospitalizedugandanfirstepisodepsychosispatients AT julietnakku evaluatingconstructandcriterionvalidityofneuroscreeninassessingneurocognitionamonghospitalizedugandanfirstepisodepsychosispatients AT nastassjakoen evaluatingconstructandcriterionvalidityofneuroscreeninassessingneurocognitionamonghospitalizedugandanfirstepisodepsychosispatients AT noelinenakasujja evaluatingconstructandcriterionvalidityofneuroscreeninassessingneurocognitionamonghospitalizedugandanfirstepisodepsychosispatients AT wilberssembajjwe evaluatingconstructandcriterionvalidityofneuroscreeninassessingneurocognitionamonghospitalizedugandanfirstepisodepsychosispatients AT christophermferraris evaluatingconstructandcriterionvalidityofneuroscreeninassessingneurocognitionamonghospitalizedugandanfirstepisodepsychosispatients AT anthonyfsantoro evaluatingconstructandcriterionvalidityofneuroscreeninassessingneurocognitionamonghospitalizedugandanfirstepisodepsychosispatients AT danjstein evaluatingconstructandcriterionvalidityofneuroscreeninassessingneurocognitionamonghospitalizedugandanfirstepisodepsychosispatients AT reubennrobbins evaluatingconstructandcriterionvalidityofneuroscreeninassessingneurocognitionamonghospitalizedugandanfirstepisodepsychosispatients |